Alzheimer’s blood tests—also called biomarker tests—usually cost between $200 and $800 without insurance, depending on the specific markers tested and the lab performing the work. Insurance coverage is inconsistent. Medicare covers some approved tests under certain diagnostic pathways, many private insurers are still developing coverage policies, and out-of-pocket costs remain a barrier for uninsured or underinsured patients. A 65-year-old with mild cognitive impairment might pay $600 out of pocket for a phosphorylated tau blood test at a private diagnostic center, while the same test could be covered entirely through Medicare or cost nothing at a hospital-based memory clinic that has adopted the test as part of standard assessment.
The landscape is shifting rapidly. The FDA has approved several blood-based biomarker tests since 2022, including tests for amyloid and tau proteins. Major insurers are beginning to cover these tests, but most have not yet published comprehensive coverage policies. For patients and families navigating early cognitive changes, understanding whether insurance will cover testing—and what to expect if it won’t—is critical to making decisions about diagnosis.
Table of Contents
- Which Alzheimer’s Blood Tests Are FDA-Approved and What Do They Cost?
- Medicare Coverage: What Is Covered and What You’ll Pay
- Private Insurance Coverage: Inconsistent and Often Conditional
- Out-of-Pocket Costs and Patient Access Barriers
- Insurance Denials and Appeals: What to Do If Your Test Is Not Covered
- Regional and Network Differences in Access
- Moving Forward: Practical Steps for Coverage and Cost
Which Alzheimer’s Blood Tests Are FDA-Approved and What Do They Cost?
The FDA has approved three main blood tests for Alzheimer’s biomarkers. The Elecsys Phosphorylated-Tau (p-tau181 and p-tau217) tests, made by Roche, were approved first, followed by tests from other manufacturers including Fujirebio and Alkermes. These measure proteins in the blood that accumulate in Alzheimer’s disease—amyloid-beta, tau, and phosphorylated tau—which previously could only be detected through expensive PET imaging or invasive spinal fluid collection. Cost ranges vary by test and setting.
Hospital-based tests often cost $300–$500, while private diagnostic laboratories charge $500–$800. Some research centers and academic medical centers offer tests at lower rates or at no cost for enrolled participants. A patient getting tested at Johns Hopkins or Mayo Clinic might pay less than someone at an independent lab—or nothing if they qualify for a research study. Insurance companies, however, often do not recognize price differences; they reimburse based on their contracted rates, which may be substantially lower than the cash price.
Medicare Coverage: What Is Covered and What You’ll Pay
Medicare coverage of Alzheimer’s blood tests is limited but growing. In 2023, Medicare began covering amyloid PET imaging in specific scenarios, and has since extended coverage to some blood-based tests when ordered as part of diagnostic evaluation for cognitive impairment. However, Medicare does not cover all blood tests for all patients. Coverage typically requires that the test be ordered by a neurologist or geriatrician and that the patient meet specific clinical criteria—usually mild cognitive impairment or subjective cognitive concerns with an objective cognitive test abnormality.
If Medicare approves your test, you typically pay 20% of the Medicare-approved amount after meeting your deductible, with no copay if your provider is in-network. If the test is not covered by Medicare, you are responsible for the full cost. Some beneficiaries have purchased supplemental coverage (Medigap) that covers the 20% coinsurance, but this varies by plan. A patient with a Medigap Plan F might pay nothing; a beneficiary with Plan G would pay 20% plus a small copay; and someone without supplemental coverage might pay several hundred dollars out of pocket.
Private Insurance Coverage: Inconsistent and Often Conditional
Private insurers are still solidifying coverage policies for Alzheimer’s blood tests. Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna have all begun covering some phosphorylated tau and amyloid tests, but each has different requirements. Some insurers require that the test be performed at an in-network lab; others require a prior authorization or documentation of cognitive decline on a formal cognitive screening tool such as the Montreal Cognitive Assessment or Mini-Cog. Prior authorization can introduce delays.
A patient referred for a blood test by their primary care doctor might wait two to four weeks for the insurer to approve the test before it can be drawn. Some insurers will approve testing only after other diagnostic steps—such as an MRI to rule out stroke or tumor—have been completed. This creates a gatekeeping scenario where the blood test is not seen as the first-line diagnostic tool but rather as a confirmation after other conditions have been ruled out. Insurers justify this on the grounds that cognitive complaints can have many causes, and blood tests alone are not diagnostic; imaging is often still needed.
Out-of-Pocket Costs and Patient Access Barriers
If your test is not covered, you face the full cash price. Most independent labs and diagnostic centers charge $500–$800 for a single Alzheimer’s blood test. Some patients have insurance but face high deductibles; a person with a $2,500 annual deductible who has not yet met it will often pay the full cash price because the test is not yet counted toward their deductible or is subject to a separate benefit tier. Others are uninsured entirely—approximately 10% of Americans under age 65 and a growing percentage of seniors in states that have not expanded Medicaid.
For uninsured patients, options are limited. Academic medical centers sometimes offer sliding-scale testing based on income. The National Institute on Aging funds research studies that provide free testing to eligible participants. Some direct-to-consumer labs such as Lab Plus or Ulta Lab Tests advertise Alzheimer’s blood tests without insurance, though these operate in a regulatory gray zone and may not provide the same quality assurance as hospital-based labs. A 58-year-old uninsured woman concerned about her memory loss might find testing costs $600 out of pocket at a private lab, but $0 if she enrolls in an Alzheimer’s research cohort—though enrollment often requires travel to a research site and time commitments.
Insurance Denials and Appeals: What to Do If Your Test Is Not Covered
Insurance denials for Alzheimer’s blood tests are common. A patient may be denied coverage because the ordering provider is not in-network, because the test was ordered for screening rather than diagnostic evaluation, or because the insurer considers it experimental—even though the FDA has approved it. When a denial occurs, patients have the right to appeal. The appeals process typically involves three levels. First, a standard appeal, where you or your doctor submits additional documentation (such as cognitive test scores, imaging results, or clinical notes) explaining medical necessity.
Second, an expedited appeal if the situation is urgent. Third, an external review by a state-appointed independent reviewer if the insurance company upholds the denial. External reviews can take 30–60 days. During this time, some patients choose to pay out of pocket rather than wait, while others delay testing. A denial is not final; many insurers will cover the test on appeal if the clinical documentation clearly establishes cognitive concern and the test is medically necessary.
Regional and Network Differences in Access
Access to Alzheimer’s blood testing and insurance coverage varies dramatically by geography. Patients in major metropolitan areas with academic medical centers—New York, Boston, San Francisco, Los Angeles—are more likely to find neurologists and geriatricians who offer these tests and have established insurance relationships. Insurers in these regions often have clearer coverage policies because they have been negotiating with providers longer.
Rural patients and those in smaller cities may have very limited access; they may need to travel 50+ miles to find a neurologist who orders blood tests, and their regional insurers may have minimal coverage guidance for the test. State Medicaid programs also differ. California and New York have begun covering Alzheimer’s blood tests through Medicaid for eligible beneficiaries, while other states have not yet addressed them. A 62-year-old on Medicaid in New York might have her test fully covered, while an identical patient in Alabama might not.
Moving Forward: Practical Steps for Coverage and Cost
If you are considering Alzheimer’s blood testing, contact your insurance company directly before scheduling the test. Ask specifically: Is this test covered? If yes, do I need prior authorization? If not, can you explain why? You can frame your question around your specific cognitive concerns or get your doctor’s office to request pre-authorization. Having pre-authorization in writing prevents surprise bills after the test is done.
If testing is denied or cost is a barrier, ask your doctor about community health centers, academic medical centers, or research opportunities in your area. Alzheimer’s Association chapters often have information about free or low-cost testing programs. Document everything—denials, appeals, and the dates you contacted your insurer—so that if a pattern emerges, you can file a complaint with your state’s Department of Insurance. Insurance practices around new medical tests often improve after feedback from patients and advocacy groups.
- —
